Alemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL).
The introduction of immunotherapeutic agents has provided renewed hope for Chronic lymphocytic leukemia fludarabine-refractory patients. Several clinical trials have shown that alemtuzumab is a more effective option compared to combination chemotherapy for treatment of patients who have relapsed or who are refractory to fludarabine, including those with poor prognostic factors. Although there are significant potential toxicities associated with alemtuzumab, such as infusional reactions and the risk of cytomegalovirus (CMV) reactivation, most are manageable. Pre-treatment anti-pyretics and anti-histamines are recommended to prevent or mitigate the acute infusional reactions associated with intravenous infusion. Recent use of alemtuzumab via the subcutaneous route has been shown to be well tolerated and has yielded similar response rates to the infusional method of administration. Prophylaxis with thrimethoprim/sulphamethoxazole (TMP/SMZ) as well as valacyclovir or a similar anti-viral can prevent many of the opportunistic infections seen in early trials. Reactivation of CMV infection can be effectively managed with monitoring and early treatment. Chemo-immunotherapy combination with alemtuzumab has been tested and demonstrated unprecedented clinical results in relapsed and refractory patients. The use of this agent earlier in the algorithm of patients with these characteristics should be considered. Future areas of research will include the use of alemtuzumab in combination with other monoclonal antibodies and other targeted therapies.
Montillo
Marco
M
Department of Oncology/Hematology, Division of Hematology and Bone Marrow Transplant Unit, Niguarda Ca' Granda Hospital, Milan, Italy.
Ricci
Francesca
F
Miqueleiz
Sara
S
Tedeschi
Alessandra
A
Morra
Enrica
E
Blood. 2004 Aug 15;104(4):948-55
15090452
Blood. 2002 Mar 15;99(6):2245-7
11877305
Immunology. 1998 Nov;95(3):427-36
9824507
N Engl J Med. 1994 Feb 3;330(5):319-22
7904047
Blood. 1995 Mar 15;85(6):1580-9
7888675
Br J Haematol. 1986 Nov;64(3):479-86
3539172
Semin Oncol. 2002 Feb;29(1 Suppl 2):75-80
11842392
Lancet. 2007 Jul 21;370(9583):230-239
17658394
Haematologica. 2005 Oct;90(10):1435-6
16219582
Blood. 2002 Aug 1;100(3):768-73
12130484
Blood. 2004 Aug 1;104(3):655-8
15073032
Leukemia. 2004 Jun;18(6):1093-101
15071604
Leuk Lymphoma. 2004 Nov;45(11):2269-73
15512816
Hematol J. 2001;2(5):300-6
11920265
N Engl J Med. 2003 Dec 25;349(26):2570-2; discussion 2570-2
14695424
N Engl J Med. 2000 Dec 14;343(24):1750-7
11114313
J Clin Oncol. 2005 May 1;23(13):2971-9
15738539
J Clin Oncol. 1997 Apr;15(4):1567-74
9193354
Cancer. 1974 Feb;33(2):555-62
4812772
Leukemia. 2006 Aug;20(8):1441-5
16738694
J Clin Oncol. 2005 Oct 1;23(28):7024-31
16145065
Clin Lymphoma. 2002 Sep;3(2):105-10
12435283
Haematologica. 2005 Mar;90(3):410-2
15749678
N Engl J Med. 1992 Oct 8;327(15):1056-61
1355853
Clin Lymphoma. 2004 Mar;4(4):220-7
15072613
N Engl J Med. 1993 Mar 18;328(11):812-3
8094889
J Clin Oncol. 2002 Sep 15;20(18):3891-7
12228210
Blood. 2002 May 15;99(10):3554-61
11986207
Blood. 1993 Jun 1;81(11):2878-84
8499626
Clin Lymphoma Myeloma. 2006 Sep;7(2):125-30
17026823
Eur J Immunol. 1993 May;23(5):1098-104
8477804
Leuk Lymphoma. 2002 May;43(5):1007-11
12148879
Med Oncol. 2002;19 Suppl:S11-9
12180487
Blood. 1996 Jun 15;87(12):4990-7
8652811
Blood. 2006 Feb 1;107(3):885-91
16219797
Leuk Lymphoma. 2002 Sep;43(9):1755-62
12685828
J Clin Oncol. 1985 Sep;3(9):1196-201
2993534
Leuk Lymphoma. 1993;10 Suppl:43-9
8097654
Cancer Treat Rep. 1979 Mar;63(3):441-7
371799
Lancet. 1996 May 25;347(9013):1432-8
8676625
Blood. 1993 Aug 1;82(3):807-12
7687895
Cancer. 2003 Aug 15;98(4):773-8
12910522
Blood. 2003 May 1;101(9):3413-5
12522009
J Clin Oncol. 2007 Mar 1;25(7):793-8
17283364
Hematology Am Soc Hematol Educ Program. 2004;:163-83
15561682
Blood. 2001 Oct 15;98(8):2319-25
11588025
Blood. 1989 Jul;74(1):19-25
2473795
Blood. 2004 May 1;103(9):3278-81
14726385
N Engl J Med. 2002 Aug 8;347(6):452-3
12167696